A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

Phase 1 Completed 295 enrolled MedImmune LLC

RandomizedParallel-groupDouble-blindTreatment

Phase 1 study to evaluate the safety of MEDI4212.

Evaluation	Drug	Modality	Dose	Route
Subject	MEDI4212	Monoclonal antibody	5 mg	Subcutaneous
Subject	MEDI4212	Monoclonal antibody	15 mg	Subcutaneous
Subject	MEDI4212	Monoclonal antibody	60 mg	Subcutaneous
Subject	MEDI4212	Monoclonal antibody	150 mg	Subcutaneous
Subject	MEDI4212	Monoclonal antibody	300 mg	Subcutaneous
Comparator	Omalizumab	Monoclonal antibody	150 mg	Subcutaneous
Comparator	Omalizumab	Monoclonal antibody	375 mg	Subcutaneous